Developer docs
API playgroundTry for free, no card

Search company profiles

Vyome Therapeutics

Full company profile

uuid000035e

Namestring
Vyome Therapeutics
Legal namestring
Vyome Holdings, Inc.
Websiteurl
vyometx.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Vyome Holdings, Inc. (Nasdaq: HIND), operating through its Vyome Therapeutics subsidiaries, is a clinical-stage specialty pharmaceutical company developing novel therapies for immuno-inflammatory and rare diseases with significant unmet medical need. The company is headquartered in Cambridge, Massachusetts, with R&D operations in Delhi, India, and operates a US-India innovation corridor model designed for capital-efficient drug development. Its core pipeline comprises three clinical-stage assets: VT-1953, a topical gel for Malignant Fungating Wounds (MFW) with orphan drug designation potential and a 75% malodor reduction observed in Phase 2; VT-1908, a non-steroidal IMPDH-targeting ophthalmic drop for uveitis that matched steroid efficacy in preclinical models; and VB-1953, a dual-action (DNA gyrase + TLR-MD2) topical for antibiotic-resistant inflammatory acne with safety data across 550+ patients.

The company's commercial revenue is derived from a licensing and marketing agreement with Sun Pharma covering reformulated topical anti-fungal products (including Luliconazole) in India, generating royalties and milestone payments. Vyome also commercializes its Molecular Replacement Therapeutics (MRT) technology platform through this partnership. The company completed a reverse merger with ReShape Lifesciences in August 2025 to become publicly listed on Nasdaq, raised capital via a concurrent private placement of approximately $7.3 million, and established a $12 million ATM facility with Maxim Group. In September 2025, Vyome acquired MIT AI startup Oculo, Inc. to build a new AI-in-healthcare business unit targeting systemic inflammation, and in May 2026 in-licensed preclinical JAK inhibitor assets from Impetis Biosciences (a TATA Enterprise). The company is positioning itself as a three-pillar healthcare platform spanning biotech, medical devices, and AI.

Short descriptiontext

Vyome Therapeutics is a clinical-stage specialty pharmaceutical company developing immuno-inflammatory therapies (VT-1953, VT-1908, VB-1953) via a US-India innovation corridor, targeting patients with malignant fungating wounds, uveitis, and drug-resistant acne, and generating royalty revenue from anti-fungal products licensed to Sun Pharma in India.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-inflammatory therapeutics, clinical-stage pharmaceuticals, topical drug development, anti-fungal formulations, rare disease therapies
Industry4 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales (Pharmaceutical Segment)
TypeOne Time License
Description

Revenue from sale of reformulated topical anti-fungal products commercialized in India. Products manufactured by third parties and sold through Sun Pharma partnership.

ir.vyometx.com
2Royalties and Milestone Payments
TypeLicensing Royalties
Description

Royalty income and milestone payments from Sun Pharma licensing agreement for Luliconazole anti-fungal product. Royalties linked to net sales value of products sold by Sun Pharma to third parties. Development and sales-based milestones earned upon completion of performance obligations.

ir.vyometx.com
3Future Product Revenue (Biotechnology Segment)
TypeSubscription Recurring
Description

Pre-revenue biotechnology segment developing clinical-stage drug candidates. Will generate revenue upon FDA approval and commercialization of VT-1953, VT-1908, and VB-1953 programs.

ir.vyometx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1VT-1953
Description

Lead clinical program - novel topical gel for treatment of malignant fungating wounds (MFW), a potentially orphan drug designated program.

vyometx.com
+2 more records
Core offering1 text field

Vyome Holdings is a clinical-stage specialty pharmaceutical company developing novel therapies for immuno-inflammatory diseases, with three lead programs: VT-1953 (topical gel for malignant fungating wounds), VT-1908 (non-steroidal eye drops for uveitis), and VB-1953 (treatment for antibiotic-resistant acne). The company also generates revenue through Sun Pharma licensing of its commercialized topical anti-fungal products (Luliconazole) in India and operates an MRT technology platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 75% reduction in malodor early efficacy analysis for VT-1953
+3 more records
Product overview1 text field

Vyome Holdings is a Cambridge, MA-based clinical-stage specialty pharmaceutical company with a US-India innovation corridor operating model. The company is building a 3-pillar platform combining Biotech & Pharma, Medical Devices, and AI in Healthcare. The core product pipeline includes VT-1953 (Malignant Fungating Wounds treatment), VT-1908 (Uveitis eye drops), and VB-1953 (Drug-Resistant Acne treatment), all targeting immuno-inflammatory diseases. The company has commercialized anti-fungal products using its MRT technology platform through Sun Pharma licensing agreements in India. Following the merger with ReShape Lifesciences (completed August 2025), Vyome trades on Nasdaq under ticker HIND and is advancing its clinical-stage assets through regulatory discussions.

Product and service1 record
1VT-1953
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-29
Description

Acquired MIT AI startup Oculo, Inc. to launch a new business unit focused on using AI to address inflammation. Plans include developing an AI psychiatrist to diagnose and treat systemic inflammation, targeting behavioral drivers and biomarkers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-10
Description

Merger agreement combining Vyome Therapeutics with ReShape Lifesciences in an all-stock transaction. Completed August 15, 2025. Combined company renamed Vyome Holdings, Inc. focused on immuno-inflammatory assets and US-India opportunities. ReShape sold most assets to Biorad Medisys for $5.16 million in cash.

Strategic tierMinorTypeOthersAnnounced on2024-07-10
Description

Asset purchase agreement where ReShape Lifesciences sold substantially all assets to Biorad Medisys for $5.16 million in cash (later adjusted to $2.25 million). Transaction completed July 8, 2025.

4Sun Pharma
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-12-01
Description

Licensing and marketing agreement with Sun Pharma group of companies for topical anti-fungal products in India. Includes reformulated anti-fungal shampoo and Luliconazole cream. Vyome receives royalties, milestone payments, and net service fee payments based on Sun Pharma's product sales. The Luliconazole agreement was commercialized in 2023.

ir.vyometx.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage dermatology specialty pharma with FDA-approved Zoryve and a pipeline targeting inflammatory skin conditions including acne and atopic dermatitis. Directly comparable to Vyome as a small-cap US dermatology/inflammation biotech pursuing topical therapies with novel mechanisms.

TypeDirect peer
Description

Clinical-stage biotech developing novel therapies for immune-mediated ocular and systemic diseases, with a primary focus on non-steroidal treatments for ocular inflammation (uveitis, dry eye). Highly comparable to Vyome's VT-1908 program targeting uveitis with IMPDH inhibition.

TypeDirect peer
Description

Specialty pharmaceutical company focused on immuno-inflammatory dermatology, developing novel topical and systemic therapies for conditions including acne and other inflammatory skin diseases. Comparable clinical-stage US biotech with similar inflammatory derm focus as Vyome.

4Cassiopea (acquired by Sun Pharma)
TypeDirect peer
Description

Specialty dermatology company that developed Winlevi (clascoterone) for acne vulgaris, a topical first-in-class therapy. Direct acne competitor and notably was acquired by Sun Pharma — Vyome's own Indian commercial partner.

TypeEmerging player
Description

Emerging ophthalmology biotech developing TRS01 and other non-steroidal therapies for uveitis and other inflammatory eye diseases. Direct competitor to Vyome's VT-1908 uveitis program with similar steroid-sparing approach.

TypeDirect peer
Description

Specialty pharma developing voclosporin for autoimmune diseases including lupus nephritis. Comparable clinical/specialty pharma model targeting immune-mediated conditions, with similar size and capital structure dynamics to Vyome.

TypeDirect peer
Description

Dermatology-focused subsidiary of Roivant Sciences developing topical therapies for inflammatory skin conditions including psoriasis and atopic dermatitis. Comparable specialty pharma focused on immuno-inflammatory derm indications similar to Vyome's pipeline.

TypeBroad incumbent
Description

Large biopharmaceutical company that acquired Horizon Therapeutics in 2023, gaining Tepezza and other specialty inflammation/immunology assets. Represents the broad incumbent landscape in immuno-inflammatory diseases that Vyome's niche programs compete against for physician mindshare and commercial resources.

9Sun Pharmaceutical Industries
TypeOthers
Description

Vyome's licensing and commercial partner for anti-fungal products in India. Also a strategic comparable in dermatology and specialty pharma in emerging markets, and a potential acquirer given its prior dermatology M&A (e.g., Cassiopea).

TypeOthers
Description

Life sciences tools and services company with nucleic acid and biologics manufacturing capabilities used by clinical-stage biotechs including those developing inflammatory disease therapies. Tangentially comparable as a small-cap public biotech adjacent to Vyome's clinical development supply chain.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vyome Therapeutics

Specialty Pharmaceuticalsvyometx.com

Vyome Therapeutics is a clinical-stage specialty pharmaceutical company developing immuno-inflammatory therapies (VT-1953, VT-1908, VB-1953) via a US-India innovation corridor, targeting patients with malignant fungating wounds, uveitis, and drug-resistant acne, and generating royalty revenue from anti-fungal products licensed to Sun Pharma in India.

What Vyome Therapeutics does

Vyome Holdings, Inc. (Nasdaq: HIND), operating through its Vyome Therapeutics subsidiaries, is a clinical-stage specialty pharmaceutical company developing novel therapies for immuno-inflammatory and rare diseases with significant unmet medical need. The company is headquartered in Cambridge, Massachusetts, with R&D operations in Delhi, India, and operates a US-India innovation corridor model designed for capital-efficient drug development. Its core pipeline comprises three clinical-stage assets: VT-1953, a topical gel for Malignant Fungating Wounds (MFW) with orphan drug designation potential and a 75% malodor reduction observed in Phase 2; VT-1908, a non-steroidal IMPDH-targeting ophthalmic drop for uveitis that matched steroid efficacy in preclinical models; and VB-1953, a dual-action (DNA gyrase + TLR-MD2) topical for antibiotic-resistant inflammatory acne with safety data across 550+ patients.

The company's commercial revenue is derived from a licensing and marketing agreement with Sun Pharma covering reformulated topical anti-fungal products (including Luliconazole) in India, generating royalties and milestone payments. Vyome also commercializes its Molecular Replacement Therapeutics (MRT) technology platform through this partnership. The company completed a reverse merger with ReShape Lifesciences in August 2025 to become publicly listed on Nasdaq, raised capital via a concurrent private placement of approximately $7.3 million, and established a $12 million ATM facility with Maxim Group. In September 2025, Vyome acquired MIT AI startup Oculo, Inc. to build a new AI-in-healthcare business unit targeting systemic inflammation, and in May 2026 in-licensed preclinical JAK inhibitor assets from Impetis Biosciences (a TATA Enterprise). The company is positioning itself as a three-pillar healthcare platform spanning biotech, medical devices, and AI.

Vyome Therapeutics firmographics

Firmographics
Name
Vyome Therapeutics
Legal name
Vyome Holdings, Inc.
Website
https://vyometx.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Vyome Therapeutics is a clinical-stage specialty pharmaceutical company developing immuno-inflammatory therapies (VT-1953, VT-1908, VB-1953) via a US-India innovation corridor, targeting patients with malignant fungating wounds, uveitis, and drug-resistant acne, and generating royalty revenue from anti-fungal products licensed to Sun Pharma in India.
Ownership category
akta.pro rank

Vyome Therapeutics industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Immuno-inflammatory therapeutics
  • Clinical-stage pharmaceuticals
  • Topical drug development
  • Anti-fungal formulations
  • Rare disease therapies

Where Vyome Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Vyome Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Product Sales (Pharmaceutical Segment): Revenue from sale of reformulated topical anti-fungal products commercialized in India. Products manufactured by third parties and sold through Sun Pharma partnership.
  2. Royalties and Milestone Payments: Royalty income and milestone payments from Sun Pharma licensing agreement for Luliconazole anti-fungal product. Royalties linked to net sales value of products sold by Sun Pharma to third parties. Development and sales-based milestones earned upon completion of performance obligations.
  3. Future Product Revenue (Biotechnology Segment): Pre-revenue biotechnology segment developing clinical-stage drug candidates. Will generate revenue upon FDA approval and commercialization of VT-1953, VT-1908, and VB-1953 programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Vyome Therapeutics product offering

Product offering

Core offering

Vyome Holdings is a clinical-stage specialty pharmaceutical company developing novel therapies for immuno-inflammatory diseases, with three lead programs: VT-1953 (topical gel for malignant fungating wounds), VT-1908 (non-steroidal eye drops for uveitis), and VB-1953 (treatment for antibiotic-resistant acne). The company also generates revenue through Sun Pharma licensing of its commercialized topical anti-fungal products (Luliconazole) in India and operates an MRT technology platform.

Product overview

Vyome Holdings is a Cambridge, MA-based clinical-stage specialty pharmaceutical company with a US-India innovation corridor operating model. The company is building a 3-pillar platform combining Biotech & Pharma, Medical Devices, and AI in Healthcare. The core product pipeline includes VT-1953 (Malignant Fungating Wounds treatment), VT-1908 (Uveitis eye drops), and VB-1953 (Drug-Resistant Acne treatment), all targeting immuno-inflammatory diseases. The company has commercialized anti-fungal products using its MRT technology platform through Sun Pharma licensing agreements in India. Following the merger with ReShape Lifesciences (completed August 2025), Vyome trades on Nasdaq under ticker HIND and is advancing its clinical-stage assets through regulatory discussions.

Differentiator

Problem solved

Functional benefit

Brands

  • VT-1953: Lead clinical program - novel topical gel for treatment of malignant fungating wounds (MFW), a potentially orphan drug designated program.
  • VT-1908
  • VB-1953

Products and services

  • VT-1953

Quantifiable outcome

  • 75% reduction in malodor early efficacy analysis for VT-1953
  • +3 more outcomes

Companies that use Vyome Therapeutics

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Vyome Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Vyome Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Oculo, Inc.coreStrategic or Co-development Partner · 29 September 2025Acquired MIT AI startup Oculo, Inc. to launch a new business unit focused on using AI to address inflammation. Plans include developing an AI psychiatrist to diagnose and treat systemic inflammation, targeting behavioral drivers and biomarkers.
  • ReShape LifesciencescoreStrategic or Co-development Partner · 10 July 2024Merger agreement combining Vyome Therapeutics with ReShape Lifesciences in an all-stock transaction. Completed August 15, 2025. Combined company renamed Vyome Holdings, Inc. focused on immuno-inflammatory assets and US-India opportunities. ReShape sold most assets to Biorad Medisys for $5.16 million in cash.
  • Biorad MedisysminorOthers · 10 July 2024Asset purchase agreement where ReShape Lifesciences sold substantially all assets to Biorad Medisys for $5.16 million in cash (later adjusted to $2.25 million). Transaction completed July 8, 2025.
  • Sun PharmacoreOEM/ Whitelabel/ Licensing Partner · 1 December 2020Licensing and marketing agreement with Sun Pharma group of companies for topical anti-fungal products in India. Includes reformulated anti-fungal shampoo and Luliconazole cream. Vyome receives royalties, milestone payments, and net service fee payments based on Sun Pharma's product sales. The Luliconazole agreement was commercialized in 2023.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Vyome Therapeutics competitors and assessment

Company assessment

Direct peers

  • Arcutis Biotherapeutics: Clinical-stage dermatology specialty pharma with FDA-approved Zoryve and a pipeline targeting inflammatory skin conditions including acne and atopic dermatitis. Directly comparable to Vyome as a small-cap US dermatology/inflammation biotech pursuing topical therapies with novel mechanisms.
  • Aldeyra Therapeutics: Clinical-stage biotech developing novel therapies for immune-mediated ocular and systemic diseases, with a primary focus on non-steroidal treatments for ocular inflammation (uveitis, dry eye). Highly comparable to Vyome's VT-1908 program targeting uveitis with IMPDH inhibition.
  • Aclaris Therapeutics: Specialty pharmaceutical company focused on immuno-inflammatory dermatology, developing novel topical and systemic therapies for conditions including acne and other inflammatory skin diseases. Comparable clinical-stage US biotech with similar inflammatory derm focus as Vyome.
  • Cassiopea (acquired by Sun Pharma): Specialty dermatology company that developed Winlevi (clascoterone) for acne vulgaris, a topical first-in-class therapy. Direct acne competitor and notably was acquired by Sun Pharma — Vyome's own Indian commercial partner.
  • Aurinia Pharmaceuticals: Specialty pharma developing voclosporin for autoimmune diseases including lupus nephritis. Comparable clinical/specialty pharma model targeting immune-mediated conditions, with similar size and capital structure dynamics to Vyome.
  • Dermavant Sciences: Dermatology-focused subsidiary of Roivant Sciences developing topical therapies for inflammatory skin conditions including psoriasis and atopic dermatitis. Comparable specialty pharma focused on immuno-inflammatory derm indications similar to Vyome's pipeline.

Emerging players

  • Tarsier Pharma: Emerging ophthalmology biotech developing TRS01 and other non-steroidal therapies for uveitis and other inflammatory eye diseases. Direct competitor to Vyome's VT-1908 uveitis program with similar steroid-sparing approach.

Broad incumbents

  • Amgen (Horizon Therapeutics): Large biopharmaceutical company that acquired Horizon Therapeutics in 2023, gaining Tepezza and other specialty inflammation/immunology assets. Represents the broad incumbent landscape in immuno-inflammatory diseases that Vyome's niche programs compete against for physician mindshare and commercial resources.

Others

  • Sun Pharmaceutical Industries: Vyome's licensing and commercial partner for anti-fungal products in India. Also a strategic comparable in dermatology and specialty pharma in emerging markets, and a potential acquirer given its prior dermatology M&A (e.g., Cassiopea).
  • Maravai LifeSciences: Life sciences tools and services company with nucleic acid and biologics manufacturing capabilities used by clinical-stage biotechs including those developing inflammatory disease therapies. Tangentially comparable as a small-cap public biotech adjacent to Vyome's clinical development supply chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Vyome Therapeutics social profiles

Digital presence

Vyome Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vyome Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Vyome Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Vyome Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vyome Therapeutics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vyome Therapeutics

What does Vyome Therapeutics do?

Vyome Holdings is a clinical-stage specialty pharmaceutical company developing novel therapies for immuno-inflammatory diseases, with three lead programs: VT-1953 (topical gel for malignant fungating wounds), VT-1908 (non-steroidal eye drops for uveitis), and VB-1953 (treatment for antibiotic-resistant acne). The company also generates revenue through Sun Pharma licensing of its commercialized topical anti-fungal products (Luliconazole) in India and operates an MRT technology platform.

Is Vyome Therapeutics a public or private company?

Vyome Therapeutics is a public company. It is classified as public and is currently operating.

When was Vyome Therapeutics founded?

Vyome Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Vyome Therapeutics based?

Vyome Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Vyome Therapeutics make money?

Three revenue lines are on record. Product Sales (Pharmaceutical Segment) is the primary driver. The others are royalties and Milestone Payments and future Product Revenue (Biotechnology Segment).

Who are Vyome Therapeutics's main competitors?

Direct peers on record are Arcutis Biotherapeutics, Aldeyra Therapeutics, Aclaris Therapeutics, Cassiopea (acquired by Sun Pharma), Aurinia Pharmaceuticals and Dermavant Sciences. Tarsier Pharma is listed as an emerging player. Amgen (Horizon Therapeutics) is listed as a broad incumbent. Others are Sun Pharmaceutical Industries and Maravai LifeSciences.

Does Vyome Therapeutics have an API?

No public API is recorded for Vyome Therapeutics.

What industry is Vyome Therapeutics in?

Vyome Therapeutics's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ticker ReportVyome Highlights VT-1953 Promise for Malignant Fungating Wound SymptomsVyome highlighted its lead topical gel VT-1953 for malignant fungating wound symptoms, which affect about 10% of advanced cancer patients. A pilot study of 15 patients showed a statistically significant reduction in odor versus placebo. The company has an orphan drug designation pending and plans a Type C meeting with the FDA.Seeking AlphaVyome appoints new CFO (NASDAQ:HIND)Vyome Holdings appointed Jerry Leonard as CFO effective September 1, 2026, succeeding interim CFO Robert Dickey IV. Leonard brings over 25 years of financial management experience, including CFO roles at VSee Health and iDoc Virtual Telehealth Solutions.BioSpaceVyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial OfficerVyome Holdings appointed Jerry Leonard as Chief Financial Officer, effective September 1, 2026. He brings over 25 years of public company finance experience and succeeds Robert Dickey, IV. Leonard will oversee financial operations, reporting, and governance.BioSpaceVyome Granted Chinese Patent Strengthening Immuno-Inflammation PortfolioVyome Holdings received a Chinese patent for its besifloxacin topical gel, covering formulation and therapeutic use claims for inflammatory acne. The patent strengthens Vyome's IP in China's $600 million acne market, supporting future partnering and licensing. The company's flagship program VT-1953 remains its primary capital priority.BioSpaceVyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026Vyome presented Phase 2 data for VT-1953 at AACR 2026, showing significant reduction in MFW malodor and pain. The gel improved malodor scores from 7.5 to 2.5 by Day 14, with 70% of patients reporting life-impact improvement versus 0% in control. No adverse effects were reported, and the company plans registrational studies.Business Wire BlogVyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026Vyome presented Phase 2 data for VT-1953 at AACR 2026, showing significant reduction in MFW-associated malodor and pain. The topical gel improved malodor scores by Day 14 (P=0.0020) and 70% of patients reported life-impact improvement, with no adverse effects. The company plans to advance VT-1953 into registrational studies.Stock TitanVyome posts 2025 results, cash runway to mid-2027Vyome Holdings, Inc. reported transformational 2025 results following a streamlined Nasdaq listing completed through a merger transaction, marking the company's first annual reporting period as a public company. The company's lead program VT-1953 delivered positive final Phase 2 results for treating symptoms of malignant fungating wounds, with an independent valuation by Destum Partners valuing the asset at approximately $1 billion after successful pivotal study, while the company maintains a clean capital structure with no debt or preferred stock and a cash runway expected through mid-2027.The Times of IndiaVyome lists on Nasdaq as HIND after ReShape merger - Times of IndiaVyome Holdings, formed by merging Vyome Therapeutics and ReShape Lifesciences, began trading on Nasdaq under ticker HIND on India's Independence Day. Vyome shareholders hold a 91.62% stake, and the company focuses on treatments for immuno-inflammatory and rare diseases. It plans to unlock value from its clinical-stage assets in the $100 billion market.citybizVyome Therapeutics Completes Merger with ReShape LifesciencesVyome Therapeutics closed its merger with ReShape Lifesciences, with the combined company trading under the name Vyome Holdings, Inc. on August 15, 2025, under the symbol HIND. The post-merger entity will trade at the open of trading on that day.AInvestVyome Therapeutics' Strategic Merger with ReShape Lifesciences: A Launchpad for US-India Biotech SynergyVyome Therapeutics completed a reverse merger with ReShape Lifesciences on August 15, 2025, creating Nasdaq-listed Vyome Holdings (HIND). The deal leverages U.S. regulatory access and India's AI-driven R&D, cutting costs by up to 60% and targeting the $100+ billion immuno-inflammatory and rare disease markets. MIT-affiliated leadership and a $1.15M NIH grant bolster financial resilience.